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The prevalence and characteristics of Helicobacter 
pylori-associated gastritis in dyspeptic patients in 
Eastern Croatia, determined by immunohistochemistry
Abstract
Background and purpose: Helicobacter pylori (Hp), which is associ-
ated with many upper gastrointestinal diseases, is found in about half of 
world’s population. Aim od this study is to reveal the prevalence and char-
acteristics of Hp-associated gastritis in dyspeptic patients in the population 
of Croatia.
Materials and methods: Retrospective analysis the data and materials 
of 871 dyspeptic patients undergoing routine endoscopy. The gastric biopsy 
specimens were stained by Hp-specific immmunohistocemical stain. Endo-
scopic and pathology findings were recorded for Hp infection and the pres-
ence of active gastritis. Nominal variables in the case of a large number of 
samples were compared using Pearson c2 test, while in the case of a small 
number of samples was used Fisher’s Exact test.
Results: In the present study determined prevalence of Hp-associated 
gastritis in the population of Croatia is 41%. Chronic active gastritis was 
found in 94% of patients with Hp infection and 5% of patients with gas-
tritis of some other etiology. Gastric mucosal atrophy was observed in 5% of 
patients older than 40 years. Intestinal metaplasia was detected in 26% of 
patients. Severe intestinal metaplasia occurs in the age group older than 60 
years.
Conclusion: This study is the first large study of Hp prevalence by his-
tological and immunohistochemical methods in Croatia, so the results of this 
study contribute to the understanding of how big a public health problem is 
Hp infection in a population of Croatia.
INTRODUCTION
Helicobacter pylori (Hp) is a spiral, Gram-negative bacterium which was discovered in 1982 by Marshall and Warren (1). Hp chroni-
cally colonizes the human stomach and is currently recognized to play 
a causative role in the pathogenesis of various gastroduodenal diseases, 
including gastritis, peptic ulcers, gastric cancer and mucosa-associated 
lymphoid tissue lymphoma (2-4).
Hp is a highly heterogeneous bacterium and its virulence varies geo-
graphically. The explanation for geographic differences in the incidence 
of gastric cancer and the role of Hp infection in gastric cancer and duo-
denal, could be the presence of different types of Hp virulence factor, 
especially CagA (cytotoxin-associated gene A), VacA (vacuolating cyto-
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tory protein). Some studies have been reported that indi-
viduals infected with CagA- positive strains of Hp are at 
a higher risk of peptic ulcer or gastric cancer than those 
infected with CagA-negative strains. In some researches 
DupA is confirmed as a risk factor for duodenal ulcer. (5)
Hp shows a remarkable allelic diversity and a large 
genetic variability, resulting that every individual is in-
fected with Hp’s unique strain, but differences between 
relatives are minimal. Rapid development of high-level 
resistance to commonly used antibiotics could be ex-
plained by a significantly higher mutation rate than found 
in many other bacteria. (6)
Several diagnostic tests are available for the detection of 
Hp and they could be divided in group of invasive and 
non-invasive tests. Each of these tests has its usefulness and 
limitations in different clinical situations. Invasive tests 
include histology, culture, rapid urease test and molecular 
methods, and they are performed through endoscopic bi-
opsy specimens. The most widely used non-invasive tests are 
urea breathing test and stool antigen. In the epidemiologi-
cal studies the most used non-invasive test is serology. (7)
Histological method of detection Hp infecton has 
been considered to be the gold standard. It is widely ava-
ilable and capable of achieving sensitivity and specificity 
of more than 95%, also has the ability to evaluate for 
pathologic changes associated with Hp infection such as 
inflammation, atrophy, intestinal metaplasia and mali-
gnancy. (7)
Besides heamtoxylin and eosin (H&E) staining of hi-
stological preparations, there are several histochemical 
staining methods that can improve visualization of mi-
croorganisms including Warthin-Starry, Modified Giem-
sa, Modified Genta, and Hp silver stain. Sensitivity of 
H&E is comparable to that of Giemsa and Genta, but the 
specificity is decreasing in low Hp density (90%). War-
thin-Starry silver staining allows an excellent visualizati-
on, but it is expensive, time consuming and the results are 
not always reliable. Some researchers showed that immu-
nohistochemical staining (IHC) with specific Hp antibo-
dies has the highest sensitivity and specificity. A signifi-
cant advantage of IHC is assessing the presence of Hp 
even if in biopsy specimen are coccoid forms of Hp. (7)
According to the Croatian national guidelines 2014, 
for the diagnosis of Hp infection should be applied a di-
fferent diagnostic approach in patients according to age. 
In the group of patients younger than 45 years, without 
alarming symptoms (weight loss, dysphagia, signs of ga-
strointestinal bleeding, palpable resistance in the stoma-
ch, iron deficiency anemia) diagnostic procedure can be 
performed through the non-invasive diagnostic methods. 
After treatment they also should be tested noninvansive-
ly to evaluate succes of therapy. For group of patients older 
than 45 years, and all those present with alarm symptoms, 
regardless of age, it is recommended to be tested with 
endoscopy and invasive methods. (8)
Guidelines from the last Consensus Conference 
(Maastricht V) did not change significantly for all popu-
lations with a prevalence of Hp infection over 20% (this 
is the case in Croatia). It was suggested that the age limit 
between non-invasive and invasive diagnostic methods of 
Hp infection should be determined by the prevalence of 
gastric cancer in a given population. (9)
METHODS
Population study
This study was conducted at Department of Pathology 
and Cytology of General Hospital Vinkovci and was ap-
proved by Ethics Committee of the General Hospital 
Vinkovci. The data and biopsy materials of dyspeptic pa-
tients undergoing routine endoscopy from two-year pe-
riod (2011 – 2012) are analyzed. Patients who were in the 
control gastroscopy after Hp eradication therapy and pa-
tients whose findings were insufficient samples were not 
taken into account.
Endoscopy and biopsy sample
Samples of gastric biopsies were taken during endos-
copy, four gastric biopsy were obtained (two from the 
antrum and two from the corpus). Two pathologists 
analyz ed samples at the Department of Pathology and 
Cytology of General Hospital Vinkovci.
Histochemistry and 
immunohistochemistry
Histological features such as gastric mucosal changes 
for any evidence of gastritis were studied on H&E-stained 
sections and was evaluated according to the updated 
Sydney system (10). The degree of bacterial load was cla-
ssified into four grades: 0 „normal“, 1 „mild“, 2 „mode-
rate“, 3 „marked“.
Immunohistochemical staining, also used by Tajalli et 
al. (11), was performed with the concentrated primary 
antibody, anti-Hp polyclonal rabbit (DakoCytomation), 
at a dilution 1:150 with Envision Flex antibody diluent, 
using the device for automated immunohistochemical 
staining AUTOSTAINER Link (Dako). Antigen cells in 
deparaffinized sections were unmasked by treatment with 
the PT-Link (109 Dako PT) in Target Retrieval Solution, 
High pH 9. The secondary antibody (streptavidin peroxi-
dase) is used from the set LSAB + System, HRP (Dako). 
Preparations are contrasted with hematoxylin 2 minutes.
Statistical analysis
Nominal variables in the case of a large number of sam-
ples were compared using Pearson c2 test, while in the case 
of a small number of samples was used Fisher’s Exact test. 
In numerical comparisons with nominal variables, with a 
normal distribution of numerical variables was used para-
metric Student’s t-test. The level of significance was p <0.05.
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RESULTS
In this study, 410 male and 461 female patients were 
included. Patients were divided into six groups: younger 
than 20 years (n = 17), 21-30 years (n = 48), 31-40 years 
(n = 96), 41-50 years (n = 146), 51-60 years (n = 235), 
older than 60 years (n = 329).
Of the total number of patients, in 41% is determined 
presence of Hp. There is no statistically remarkable diffe-
rence between the sexes (p = 0.531). The prevalence of Hp 
infection by age groups is shown in Table 1.
In the age group 41-50 years occurs the plateau of Hp 
infection (48%), followed by decreasing to 40% in the age 
group older than 60.
Hp was found in the antrum and corpus of 77% of 
patients, in 19 % only in the corpus and in 4% only in 
the antrum. The intensity of the Hp according to localiza-
tion is shown in Table 2.
Chronic active gastritis was found in 94% patients in 
Hp positive group and in 5% patients in Hp negative 
group. Pangastritis prevalents in both sexes (men 68% 
and women 62%). After pangastritis in men is more com-
mon antral gastritis (20%), while in women corpus gas-
tritis (24%). c2 test showed a statistically remarkable dif-
ference in the occurrence of chronic active gastritis in 
relation to the region of the stomach between the sexes (p 
= 0.005).
Analysis of the components of inflammation in the 
mucosa of the stomach has shown that in the antrum and 
corpus predominates moderate acute component of in-
flammation (2+) and marked chronic inflammation (3+). 
Remarkable correlation between the Hp and acute in-
flammatory components was found in the antrum of both 
sexes, while in the corpus is confirmed only in men (with 
correlation coefficient r ranging from ± 0.40 to ± 0.70). 
In the antrum in both sexes and in the corpus in men 
exists mild correlation between the Hp and chronic in-
flammation (r ± 0.20 to ± 0.40).
Atrophy of the gastric mucosa is found in 5% patients 
in Hp positive group, and in 3.5% patients Hp negative 
group. In Hp positive group the antrum is atrophic 
changed in 72% patients, the corpus in 22%, and in 6% 
of patients atrophy affects antrum and corpus. Severe at-
rophy occurs in patients older than 60 years.
Intestinal metaplasia of gastric mucosa was found in 
26% patients in the Hp positive group and in 25% pa-
tients in the Hp negative group. In 88% patients intesti-
nal metaplasia was found in the antrum, in 8% engages 
the antrum and corpus, and in 4% patients was found 
only in the corpus. The most of the patients had mild 
metaplasia, while severe metaplasia occurs only in the 
group of patients older than 60 years.
In Table 3 are comparatively shown the most remark-
able changes (Hp, intestinal metaplasia, atrophy) in rela-
tion to the localization.
Table 1. The prevalence of Hp infection by age groups
Hp+ (n) Hp– (n) Hp+ (%) Hp– (%)
≤20 3 14 18 82
21–30 14 34 29 71
31–40 41 55 43 57
41–50 71 75 48 52
51–60 98 137 42 58
>60 133 196 40 60
Hp: Helicobacter pylori
Table 2. The intensity of the Hp according to localization
Hp (n) Hp (%)
+ ++ +++ + ++ +++
Antrum 77 107 106 26 37 37
Corpus 75 163 107 22 47 31
Hp: Helicobacter pylori








Antrum 4 72 88






It is assumed that about 50% of the world’s population 
is infected with Hp. Seroprevalence of Hp infection in the 
population differs in developing and developed countries. 
Serologic indicators of Hp infection in developed coun-
tries are rarely positive in children younger than 10 years 
and prevalence grow to 10% in age group 18-30 years, 
whereas the maximum (50%) of the infection is reached 
only after the age of 60 (12). Developing countries are 
characterized by the majority of children infected before 
the age of 10, with a plateau of the infection (over 80%) 
before the age of 50 (13, 14)
Epidemiological studies frequently are using serologi-
cal tests for Hp infection detection, because of their inex-
pensiveness, rapidity and acceptability to patients. Sero-
logical tests are useful for evaluation of Hp infection in 
children. The other advantage of serological test is that 
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the accuracy of serological tests is not affected by ulcer 
bleeding, gastric atrophy as well as the use of PPI or anti-
biotics, which cause false negative results in other invasive 
or noninvasive tests. Because the serological tests detect 
antibodies that can persist in the blood for long periods 
after infection is cured, they do not distinguish between 
active infection and past exposure and are not suitable for 
evaluation in the eradication therapy. (15)
Croatia is located at the crossroads of Mediterranean, 
Central and Southeast Europe. In Europe, the prevalence 
of Hp seems to be lower in Northern countries (the Neth-
erlands 32%) than in Southern (Portugal 84%) and East-
ern countries (Turkey 83%) (16). Review article, which 
covers 22 of the 35 European countries, based on 44 stud-
ies, cites prevalence which ranges from 17% in Denmark 
to 88% in Russia (17). In Croatian population in 1997 
seroprevalence of Hp infection was between 60% and 
68% (18). The latest epidemiological study in Croatia, 
conducted ELISA, showed seroprevalence of Hp infection 
92% in dyspeptic patients and 64% in the control group 
of voluntary blood donors (19).
This study is the first large study of Hp prevalence by 
histological and immunohistochemical methods in Croa-
tia, so the results of this study contribute to the under-
standing of how big a public health problem is Hp infec-
tion in a population of Croatia.
The prevalence of Hp infection in this study is deter-
mined to be 41% putting Croatia between developed and 
developing countries, which can be compared with the 
results of histological studies: 71% in Turkey (20), 69% 
in Morocco (21), 66% in Vietnam (22), 62% in Bhutan 
(23), 50% in India (24), 54% of Albanians and 34% of 
the Greeks (25), 42% in Hungary (17), 38% in Canada 
(16), 4% to 29% in large sample of patients (78,985) from 
35 U.S. states (26), Puerto Rico and Colombia, 15% in 
Belgium (17), 7% in 251 patients in USA (27).
The plateau of Hp infection occurs in the age group 
41-50 years (48%), which coincides with the research Jo-
utei et al. in Morocco (21), while Sonnenberg et al. (27) 
states plateau at the age group 30-39 years.
Vilaichone et al. (23) reported decreasing of the preva-
lence of Hp infection in the population older than 60 
(43%) which correlates with our results, in contrast to 
Nguyen et al. (22) which quotes the increase in prevalen-
ce (75%) in the same age group.
Chronic active gastritis was present in 94% patients in 
Hp positive group, while in the Hp negative group is pre-
sent in only 5% patients. Nguyen et al. (22) cites 83% of 
chronic active gastritis in the Hp positive group, which 
correlates with our research. In other studies whose results 
were compared, the percentage of patients with chronic 
active gastritis is less than 40% (24, 27, 28).
Remarkable correlation is reported between the seve-
rity of gastritis and grade of Hp infection which is in 
accordance with several other authors (29-31).
Gastric mucosal atrophy was observed in 5% of pati-
ents which can be compared with study in India (24) and 
was lower than in other studies: in Vietnam 85% (22), in 
Sweden 55% (28), in Italy 24% (32), in Iran 45% (33).
Our results show intestinal metaplasia of gastric mu-
cosa in 26% patients in the Hp positive group and in 25% 
patients in the Hp negative group. Other researches show 
a lower percentage of patients with intestinal metaplasia 
of the stomach mucose: in Turkey 18% (20), in Vietnam 
15% (22), in USA 2% to 17% (27), in India 2% (24).
The recommended primary therapy for Hp infection 
includes: a proton pump inhibitor (PPI) and antibiotic 
(clarithromycin, and amoxicillin or metronidazole). Re-
cent studies have shown a significant decline in the ef-
fectiveness of conventional therapy, caused by an increase 
in primary resistance of Hp to clarithromycin. Although 
the primary resistance to metronidazole in many Euro-
pean countries is relatively high, this problem can be 
overcome by increasing the dose and longer treatment or 
the addition of bismuth preparations.
In addition to conventional therapy, there is sequential 
therapy based on the hypothesis that during the first stage 
treatment amoxicillin reduces the number of mutants 
resistant to clarithromycin, so that in the second stage of 
the therapy application of clarithromycin is more effi-
ciently. Sequential therapy is conducted such that the first 
five days administered amoksiclin + PIP, then the next 
five days clarithromycin + metronidazole + PPI
After the failure of PPI-triple therapy (PPI-metronida-
zole-amoxicillin) for 10-14 days or sequential therapy for 
a period of 10 days, in the guidelines recommended ther-
apy is quad therapy with bismuth – 10 days or PPI triple 
therapy which contains levofloxacin – 10 days. (8)
CONCLUSIONS
The prevalence of Hp infection in this study is deter-
mined to be 41% putting Croatia between developed and 
developing countries.
Chronic active gastritis was present in 94% patients in 
Hp positive group. Pangastritis prevalents in both sexes 
(men 68% and women 62%). After pangastritis in men is 
more common antral gastritis (20%), while in women 
corpus gastritis (24%).
Atrophy of the mucosa of the stomach was found in 
5% of patients, and severe atrophy occurs in age group 
older than 60 years.
Complete (intestinal) metaplasia was found in 26% 
and incomplete metaplasia in 1% of patients. In all age 
groups most of the patients had mild intestinal metaplasia.
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